All News
First day in Numbers 🔢 #EULAR2019
👉🏻 More than 9⃣ million of impressions
👉🏻 Almost 4⃣ thousand Tweets 🐦
👉🏻 From 965 participants #RheumaTwitters
Data from the Healthcare Hashtag Project - Symplur @symplur
🔗
https://t.co/Ib2D1WP09q https://t.co/GIncIijmFs
Juan Ovalles, MD, PhD DrJuanOvalles ( View Tweet)
Interstitial lung disease occurs in about half of all patients with systemic sclerosis; of these, about one-third will experience lung disease progression. "[Patients] needs to be screened [with high resolution CT] because a lung function test is not enough." #EULAR2019
CreakyJoints.org CreakyJoints ( View Tweet)
GiACTA part 2 - the morning has arrived! Disappointment or hope for tocilizumab in GCA? I'll be live tweeting it as we go.
Here's the abstract to start you off:
https://t.co/qtH8E5rVrB
#EULAR2019 OP0140 @RheumNow
David Liew drdavidliew ( View Tweet)
Positive results presented so yes, interest in molecules beyond JAKi. All good for people esp once patents finish! #EULAR2019 https://t.co/beW9GblqdF
Dr Irwin Lim _connectedcare ( View Tweet)
Look at this list of Biosimilars to TNFis! How would you decide what to use? The cost to the payer & what might be imposed? #EULAR2019 https://t.co/DhshdumsXO
Dr Irwin Lim _connectedcare ( View Tweet)
In GCA, concomitant PMR might separate out better prognosis phenotype. Mortality benefit in PMR-relevant OR 0.68 (0.58-0.80). Phenotypes important moving forward in therapeutic selection? #EULAR2019 THU0295 from U La Paz, Madrid @RheumNow https://t.co/4viMygbTcP
David Liew drdavidliew ( View Tweet)
Good morning #EULAR2019 delegates. Come by and visit, meet the Editor! https://t.co/DagNuxGfDq
The Journal of Rheumatology jrheum ( View Tweet)
Cool data presented at #EULAR2019 by @CreakyJoints #ArthritisPower https://t.co/ZtFUsEiboR
Seth D. Ginsberg SethSaidSo ( View Tweet)
Think: Do you really need to repeat another ANA test?🤔
👉🏼Repeat Antinuclear #antibody testing after a negative result had limited utility in diagnosis of ANA associated rheumatological conditions
Via Ai Li Yeo #EULAR2019 OP0020
@RheumNow
#immunology #rheumedu https://t.co/eK7GTRn8Z7
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
OP0315. In ERA CATCH cohort fatigue final improvement lags behin remission by approx 6 months. So tell pts with RA that maximal improvement in fatigue lags a bit. #EULAR2019 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
New #EULAR2019 data finds a link between vitamin D deficiency and disease activity among #spondyloarthritis patients. This could help explain the cause of "osteoporosis related to spondyloarthritis, and may adversely affect the patient’s functional status and quality of life."
CreakyJoints.org CreakyJoints ( View Tweet)
There is no clear relationship between ANCA titer and vasculitis relapse, but patients with negative ANCA seem to have less relapses. #EULAR2019 #vasculitis
Jesús Loarce JesusLoarce ( View Tweet)
Congratulations to @Yuz6Yusof, awarded best #EULAR2019 abstract!
His work
👉🏼recommended monitoring immunoglobulins baseline & b4 rituximab cycles to identify patients at risk of severe infections https://t.co/bOdwVLlXnL
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
Interesting discussion about nocebo effect when swapping to biosimilars. “Cheaper” may trigger this.
Health professionals need to understand we are salespeople in many situations. Language, trust, style matter.
#EULAR2019 https://t.co/29GP6cmXhQ
Dr Irwin Lim _connectedcare ( View Tweet)
Optimal bimekizumab dose in PsA still remains to be determined.
Stefan Siebert StefanSiebert1 ( View Tweet)
Ritchlin: Bimekizumab (anti-IL17A & F) Phase 2B in active PsA = rapid response but also further increases wk12 to wk20 and sustained to wk48.
#eular2019 @RheumNow https://t.co/yblCNmTxR4
Stefan Siebert StefanSiebert1 ( View Tweet)
@_connectedcare @RheumNow Certainly good rationale for also blocking IL-17F from pathophysiology point of view but will need to see if leads to diffs in RCTs…may also be important for IBD/other conditions
Stefan Siebert StefanSiebert1 ( View Tweet)
@StefanSiebert1 @RheumNow Do you think (gut feel) the combined inhibition of A & F looks better than IL17A inhibition alone? I know hard to compare without H2H but given you’re in this field of research...#eular2019
Dr Irwin Lim _connectedcare ( View Tweet)
RELIEF clinical trial to evaluate efficacy a treatment for #Behçet's Syndrome.. #Apremilast 30 BID demonstrated efficacy at week 12 decreases activity in number and pain of oral ulcers.. - Gulen Hatemi #EULAR2019 https://t.co/iQHErUBIeO
Dr.Martínez MtzReuma ( View Tweet)
GIACTA follow-up #eular2019
RT @drdavidliew: Flares: well, I had hoped for more from that top highlighted line. What is going to happen to our real-life patients who have had a year of TCZ and then come off? https://t.co/iGQN5HjADd
Dr Irwin Lim _connectedcare ( View Tweet)